Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation
Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation
复制标题
DOI：
10.1182/bloodadvances.2018020883
复制
发表时间：
2018-10-09
期刊：
影响因子：
7.5
通讯作者：
Dvorak, Christopher C.
中科院分区：
文献类型：
--
作者：
Schuetz, Catharina;Hoenig, Manfred;Dvorak, Christopher C.
新发自身免疫性溶血性贫血（AIHA）发生在2%至6%的造血干细胞移植（HSCT）后儿科患者中，是一种重要的并发症。HSCT后不完全的免疫恢复可能会导致免疫失调，包括自身免疫性血细胞减少症。我们描述了一种蛋白酶体抑制难治性AIHA的创新疗法。在HSCT背景下可能危及生命的AIHA中，达雷妥尤单抗可能是一种有效的补救治疗。
New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.